Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Document › Details

InfanDx AG. (2/4/21). "Press Release: Neonatal Diagnostics Company InfanDx Appoints Achim Plum as CEO". Cologne.

Organisations Organisation InfanDx AG
  Organisation 2 SphingoTec GmbH
  Group SphingoTec (Group)
Products Product InfanDx HypoxE-test
  Product 2 molecular diagnostics
Persons Person Plum, Achim (InfanDx 202102– CEO before SphingoTec + Curetis/OpGen + Siemens + Epigenomics)
  Person 2 Kintzel, Wolfgang (Ayoxxa 201802 Managing Director + Science to Market Venture Capital + CEVEC Pharmaceuticals + Direvo)

InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced the appointment of Dr. Achim Plum as sole Managing Director and Chief Executive Officer (CEO). Dr. Plum succeeds Ron Meyer, who founded the Company at the Life Science Incubator at the Center of Advanced European Studies and Research (cesar) in Bonn, Germany, and, following the successful start-up phase, relocated the Company to BioCampus Cologne.

Dr. Achim Plum has more than 20 years of management experience in the life science and diagnostics industry. During his career, Dr. Plum gained broad expertise in all aspects of in vitro diagnostics research, development, regulatory clearance, and commercialization, and focused on innovative biomarkers, personalized medicine and diagnostic solutions for point-of-care and near-patient testing.

“We are very pleased that we could win Dr. Plum to lead the Company through the next phases of product development and commercialization. His broad diagnostics expertise and industry network will be key to the further growth and success of InfanDx,” commented Wolfgang Kintzel, Chairman of InfanDx’ Supervisory Board. “I also would like to take the opportunity to thank Ron Meyer, the founding CEO of InfanDx, for his tireless efforts in biomarker research and collaborative clinical development that the Company can now build on. On behalf of the Supervisory Board, I wish him all the best with his future endeavors.”

“I am very much looking forward to working with the InfanDx team and Supervisory Board. The Company has established an outstanding network of scientific and clinical collaborators to make a difference for the youngest and most vulnerable of all patients. Our InfanDx HypoxE-test® in development has the potential to help improving outcomes for newborns suffering from brain damage caused by perinatal asphyxia, providing these children with a chance of a life without disabilities,” said Dr. Achim Plum, CEO of InfanDx.

InfanDx HypoxE-test® is the Company’s proprietary lead product in clinical development. It is based on a panel of proprietary biomarkers and designed for the rapid and reliable diagnosis of perinatal asphyxia (oxygen deficit during birth) and early identification of hypoxic-ischemic encephalopathy (HIE) within the first hours of birth. HIE as a consequence of perinatal asphyxia (oxygen deficit during birth) can result in life-long disabilities of the children affected. The long-term detrimental effects of HIE can be mitigated and even prevented by neuroprotective hypothermia treatment initiated within six hours of birth, provided that affected newborns can be reliably and timely identified by suitable diagnostic methods.

Prior to joining InfanDx, Dr. Plum has been Managing Director of SphingoTec GmbH (Hennigsdorf/Germany), a company developing and commercializing innovative diagnostic solutions in acute and critical care. Prior to that,he held the position of CBO and Executive Board Member of the publicly listed Curetis Group (Stuttgart, Germany), now OpGen Group (Gaithersburg, MD, USA), a company focusing on rapid molecular infectious disease diagnostics for near-patient testing. He also was founding Managing Director of Ares Genetics GmbH (Vienna/Austria), a digital diagnostics company and subsidiary of Curetis GmbH focusing on AI-powered molecular antibiotic susceptibility prediction. Prior to Curetis, Dr. Plum held a senior management position at Siemens Healthineers, where he was responsible for Diagnostic and BioScience Technology & Innovation. Dr. Plum started his career in diagnostics at the cancer diagnostics company Epigenomics (Berlin, Germany), lastly as Senior Vice President Business & Strategy. Dr. Plum studied genetics, cell biology and biochemistry in Bonn, Germany, and Norwich,UK. He obtained his Ph.D. in Molecular Genetics from the University of Bonn in 1999. For more information see:


About InfanDx

InfanDx AG is a privately held company incorporated in 2010 in Cologne, Germany, focusing on the development and commercialization of diagnostic solutions for newborns.

The Company’s proprietary lead product in clinical development is the InfanDx HypoxE-test® designed for the reliable identification of hypoxic-ischemic encephalopathy (HIE) within the first hours of birth. HIE as a consequence of perinatal asphyxia (oxygen deficit during birth) can result in life-long disabilities. The long-term detrimental effects of HIE can be mitigated and even prevented by neuroprotective hypothermia treatment. However, this burdensome therapy has to be initiated within six hours of birth to be effective, requiring suitable diagnostic methods to reliably and timely identify the affected newborns.

While standard-of-care diagnostic methods cannot deliver a conclusive diagnosis of HIE within this time frame, the rapid InfanDx HypoxE-test® is designed to support clinicians in the timely decision whether newborns require neuroprotective hypothermia treatment. For more information, please visit:

For further information, please contact:

InfanDx AG
Dr. Achim Plum (CEO)
T: +49 (0) 221 29271401

Media contact
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68

Record changed: 2021-07-30


Picture [iito] Made Without Love 650x80px

More documents for InfanDx AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top